We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+69.32%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$408M
AUM Growth
+$136M
Cap. Flow
+$68.1M
Cap. Flow %
16.68%
Top 10 Hldgs %
29.1%
Holding
175
New
29
Increased
78
Reduced
38
Closed
27

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$8.17M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.71M
3
INSM icon
Insmed
INSM
+$4.7M
4
CDTX
Cidara Therapeutics
CDTX
+$4.52M
5
ACLX
Arcellx
ACLX
+$4.35M

Top Sells

Rank Stock Value
1
ANSS
Ansys
ANSS
+$6.01M
2
JNPR
Juniper Networks
JNPR
+$4.58M
3
HES
Hess
HES
+$4M
4
AMED
Amedisys
AMED
+$3.86M
5
WDC icon
Western Digital
WDC
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 59%
2 Technology 12.01%
3 Industrials 6.97%
4 Financials 4.64%
5 Consumer Discretionary 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AFRM icon
126
Affirm
AFRM
$25.7B
$914K 0.22%
+12,500
New +$951K
NAMS icon
127
NewAmsterdam Pharma
NAMS
$3.3B
$905K 0.22%
31,831
+12,557
+65% +$301K
ETR icon
128
Entergy
ETR
$49.7B
$895K 0.22%
9,600
-5,700
-37% -$501K
KYMR icon
129
Kymera Therapeutics
KYMR
$9.11B
$890K 0.22%
+15,728
New +$709K
BKNG icon
130
Booking.com
BKNG
$160B
$848K 0.21%
3,925
-5,000
-56% -$1.12M
CTMX icon
131
CytomX Therapeutics
CTMX
$752M
$820K 0.2%
+257,148
New +$579K
JD icon
132
JD.com
JD
$43.1B
$818K 0.2%
23,383
+4,200
+22% +$137K
CPNG icon
133
Coupang
CPNG
$29.7B
$774K 0.19%
24,050
-18,950
-44% -$573K
TCOM icon
134
Trip.com Group
TCOM
$29.1B
$734K 0.18%
9,756
+1,300
+15% +$86.9K
CELC icon
135
Celcuity
CELC
$4.3B
$676K 0.17%
+13,680
New +$548K
BABA icon
136
Alibaba
BABA
$306B
$671K 0.16%
3,757
– –
URGN icon
137
UroGen Pharma
URGN
$2.3B
$636K 0.16%
+31,886
New +$573K
NBIS
138
Nebius Group N.V.
NBIS
$49.1B
$584K 0.14%
+5,200
New +$361K
ALC icon
139
Alcon
ALC
$36.4B
$466K 0.11%
7,862
+1,739
+28% +$145K
BZ icon
140
Kanzhun
BZ
$7.49B
$442K 0.11%
18,900
-12,500
-40% -$268K
WVE icon
141
Wave Life Sciences
WVE
$993M
$434K 0.11%
59,261
+23,303
+65% +$189K
NOK icon
142
Nokia
NOK
$52.7B
$399K 0.1%
82,900
-600
-0.7% -$2.71K
AVTX icon
143
Avalo Therapeutics
AVTX
$1.04B
$353K 0.09%
+27,778
New +$239K
INBX icon
144
Inhibrx
INBX
$1.36B
$257K 0.06%
+7,626
New +$188K
TAL icon
145
TAL Education Group
TAL
$6.75B
$220K 0.05%
19,600
+1,500
+8% +$16.1K
BEKE icon
146
KE Holdings
BEKE
$18.7B
$217K 0.05%
+11,400
New +$214K
AURA icon
147
Aura Biosciences
AURA
$832M
$168K 0.04%
+27,174
New +$178K
MLTX icon
148
MoonLake Immunotherapeutics
MLTX
$1.41B
$137K 0.03%
19,059
-1,894
-9% -$98.7K
ADBE icon
149
Adobe
ADBE
$105B
– –
-3,200
Closed -$1.24M
AMED
150
DELISTED
Amedisys
AMED
– –
-39,250
Closed -$3.86M
3 4 5
6
7

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q3 2025 Portfolio in Review

As of Q3 2025, HighVista Strategies held 175 positions worth $408M, up 50% from $272M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies deployed $68.1M of net new capital in Q3 2025, opening 29 new positions and adding to 78 existing holdings. Its largest new stake was Cidara Therapeutics: 70,904 shares worth $6.79M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 38% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Western Digital, an estimated $2.97M trimmed.

  • HighVista Strategies's largest Q3 2025 buy was Cidara Therapeutics: 70,904 shares worth $6.79M.
  • HighVista Strategies added most to Abivax in Q3 2025, an estimated $8.17M increase.
  • HighVista Strategies's biggest Q3 2025 reduction was Western Digital, cutting an estimated $2.97M.
  • HighVista Strategies fully exited Ansys in Q3 2025, selling an estimated $6.01M.
  • HighVista Strategies's ten largest holdings make up 29% of its $408M portfolio in Q3 2025.
  • HighVista Strategies opened 29 new positions and closed 27 in Q3 2025.
  • HighVista Strategies's portfolio value rose 50% quarter-over-quarter to $408M.

Based on HighVista Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.